Table 2.
Pheno-type | Chr | Lead-SNP BP | MAF | P | B | SE | Genomic region | Candidate gene | Position of functional candidate gene | Functional link | Region in strong LD with lead-SNP, r2 > 0.8 |
---|---|---|---|---|---|---|---|---|---|---|---|
LDL-C | 2 | 82,111,387 | 0.10 | 4.60E−07 | − 6.78 | 1.34 | Intron, FCHO2 | FCHO2 | 82,117,891-82,248,407 | The FCHO2 gene product is involved in clathrin-mediated endocytosis of LDL-C31 | 81,958,868-82,859,296 |
Csta | 3 | 15,599,531 | 0.08 | 7.30E−07 | − 4.24 | 0.86 | Intron, CALN1 | n/a | n/a | 15,580,136-15,637,077 | |
Des | 6 | 157,486,305 | 0.19 | 1.06E−11 | − 13.58 | 2.00 | Intron, DHCR24 | DHCR24 | 157,483,794-157,519,059 | DHCR24 encodes the enzyme that converts desmosterol to cholesterol32,33 | 157,481,935-157,486,331 |
Sint | 7 | 57,828,885 | 0.22 | 3.62E−07 | 18.54 | 3.64 | Intron, LINGO1 | n/a | n/a | 57,707,845-60,000,893 | |
Bsit | 13 | 53,636,117 | 0.39 | 2.57E−07 | − 41.50 | 8.05 | Intergenic | n/a | n/a | 53,062,778-54,254,135 | |
Sphy | 13 | 75,586,650 | 0.32 | 1.30E−08 | − 106.55 | 18.74 | Intergenic | n/a | n/a | 75,586,650-75,723,225 | |
Cste | 13 | 79,228,431 | 0.47 | 2.58E−07 | − 65.28 | 12.67 | Intergenic |
FAIM FOXL2 |
79,398,049-79,411,772 79,708,693-79,709,825 | FAIM deficiency enhances SREBP signaling and promotes lipogenesis in liver34. FOXL2 represses expression of Star, which controls cholesterol transport in mitochondria35,36 | 79,109,893-79,247,374 |
Sint | 13 | 88,500,932 | 0.53 | 2.37E−07 | 15.30 | 2.96 | Intergenic | CP | 89,398,185-89,463,223 | CP encodes ceruloplasmin. Ceruloplasmin concentrations are correlated with serum triglyceride and cholesterol levels37 | 88,087,429-89,821,031 |
Lat | 13 | 88,852,202 | 0.50 | 3.38E−07 | 8.02 | 1.57 | Intergenic | CP | 89,398,185-89,463,223 | Do | 88,084,836-90,249,783 |
Des | 13 | 89,367,223 | 0.48 | 4.67E−07 | 8.48 | 1.68 | Intron, HPS3 | CP | 89,398,185-89,463,223 | Do | 88,084,836-91,010,648 |
TC | 13 | 89,563,053 | 0.47 | 2.84E−07 | 4.65 | 0.91 | Intergenic | CP | 89,398,185-89,463,223 | Do | 88,084,836-89,993,057 |
Lan | 15 | 127,265,666 | 0.20 | 8.43E−08 | 0.57 | 0.11 | Intron, NYAP2 | n/a | 127,032,688-127,295,095 | n/a | 127,263,233-127,267,733 |
Summary data of lead-SNPs surpassing the genome-wide (p < 4.8E−08) or suggestive (p < 4.8E−07) significance level. Results are listed in chromosomal and positional order. Chromosome number (Chr) and base-pair (BP) position refer to pig genome assembly Sscrofa 11.1. MAF = minor allele frequency. P = p value. B = regression coefficient. SE = standard error for B. r2 = The squared correlation coefficient between pairs of SNPs as a measure for linkage disequilibrium (LD). Phenotype abbreviations: Serum levels of the following lipids, Lanosterol (Lan), Lathosterol (Lat), Desmosterol (Des), Sum of intermediates in the cholesterol synthesis pathway (Sint) i.e. Lan + Lat + Des, Betasitosterol (Bsit), Campesterol (Cste), Stigmasterol (Stig) Sum of phytosterols (Sphy) i.e. Bsit + Cste + Stig, Coprostanol (Csta), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC).